Article
Novel RAF-directed approaches to overcome current clinical limits and block the RAS/RAF node.
Molecular oncology - 1 Jun 2024
Scardaci Rossella, Berlinska Ewa, Scaparone Pietro, Vietti Michelina Sandra, Garbo Edoardo, Novello Silvia, Santamaria David, Ambrogio Chiara
Abstract excerpt
Mutations in the RAS-RAF-MEK-ERK pathway are frequent alterations in cancer and RASopathies, and while RAS oncogene activation alone affects 19% of all patients and accounts for approximately 3.4 million new cases every year, less frequent alterations in the cascade's downstream effectors are als...
Topics
- Humans
- ras Proteins
- raf Kinases
- Neoplasms
- Animals
- Protein Kinase Inhibitors
- Mutation
- Proto-Oncogene Proteins B-raf
- Signal Transduction
- Molecular Targeted Therapy